Pancancer analysis reveals the role of disulfidptosis in predicting prognosis, immune infiltration and immunotherapy response in tumors

Juntao Huang,Ziqian Xu,Dahua Chen,Chongchang Zhou,Yi Shen

DOI: https://doi.org/10.1097/md.0000000000036830

IF: 1.6

2024-01-10

Medicine

Abstract:Malignant tumors appear to be a global health problem threatening human life and leading to death. [ 1 , 2 ] For patients with solid tumors, surgical resection combined with pre- and/or postoperative individual comprehensive treatment is considered the major choice; nevertheless, for advanced tumors, which always exhibit poor prognosis, surgical treatment may not promote satisfactory results and negative incisal margins. [ 3 , 4 ] In addition, for nonsolid cancers (e.g., hematologic tumors), precise chemotherapy is considered the preferred treatment under the recommendation guidelines. [ 5 ] However, existing therapeutic plans have several limitations, and patients may suffer from tumor recurrence, lymph node metastasis and even distant metastases after systematic treatment. [ 6–8 ] Therefore, more precise and effective medical technology is still necessary and essential for further detailed and precise treatment. During the past decades, with the development of life science, immunotherapy has achieved beneficial results in several tumors (e.g., melanoma). [ 9 , 10 ] Specifically, immune checkpoint inhibitor (ICI) therapy has become the major immunotherapeutic plan by restraining the expression of related genes and activating the patient's own immune system. [ 11 ] However, not all patients can benefit from immunotherapy due to the complex tumor immune microenvironment (TIME). [ 12 , 13 ] Immune tolerance, escape and silencing are the most common problems leading to immunotherapy failure. [ 14 ] Therefore, a detailed assessment of the TIME is important and crucial for guiding clinical treatment.

medicine, general & internal